Copied
 
 
2022, DKK
16.06.2023
Bruttoresultat

333''

Primær drift

42.630'

Årets resultat

33.548'

Aktiver

447''

Kortfristede aktiver

417''

Egenkapital

49.140'

Afkastningsgrad

10 %

Soliditetsgrad

11 %

Likviditetsgrad

123 %

Resultat
16.06.2023
Årsrapport
2022
16.06.2023
2021
17.05.2022
2020
15.06.2021
2019
03.06.2020
2018
24.05.2019
2016
03.05.2018
Nettoomsætning509.919.862373.940.044330.145.351363.935.809341.939.236317.442.873
Bruttoresultat333.172.771311.890.965276.132.396134.886.410119.226.948111.632.649
Resultat af primær drift42.630.30530.231.50128.207.6148.811.0376.162.2126.887.961
Indtægter af kapitalandele (tilknyttede og associerede) 000000
Finansielle indtægter2.356.913474.522822.093398.140421.608564.250
Finansieringsomkostninger-952.921-2.060.749-1.021.898-909.538-335.098-365.820
Andre finansielle omkostninger000000
Resultat før skat44.034.29728.645.27428.007.8098.299.6396.248.7227.086.391
Resultat33.547.90421.405.17921.277.9605.251.8104.213.0515.378.615
Forslag til udbytte-33.500.000-21.400.000-21.000.000000
Aktiver
16.06.2023
Årsrapport
2022
16.06.2023
2021
17.05.2022
2020
15.06.2021
2019
03.06.2020
2018
24.05.2019
2016
03.05.2018
Kortfristede varebeholdninger000000
Kortfristede tilgodehavender fra salg og tjenesteydelser 416.763.703267.700.983237.312.58400101.519.736
Likvider00326.474.370137.161.04329.448.96421.595.659
Kortfristede aktiver416.763.703267.700.983563.786.954148.278.010128.533.590123.115.395
Immaterielle aktiver og goodwill000000
Finansielle anlægsaktiver000000
Materielle aktiver29.970.12115.719.41221.184.4811.329.7411.506.5921.683.443
Langfristede aktiver29.970.12115.719.41221.184.4811.329.7411.506.5921.683.443
Aktiver446.733.824283.420.395584.971.435149.607.751130.040.182124.798.838
Aktiver
16.06.2023
Passiver
16.06.2023
Årsrapport
2022
16.06.2023
2021
17.05.2022
2020
15.06.2021
2019
03.06.2020
2018
24.05.2019
2016
03.05.2018
Forslag til udbytte33.500.00021.400.00021.000.000000
Egenkapital49.140.44836.992.54436.587.36515.343.47610.091.6665.878.615
Hensatte forpligtelser38.071.56037.861.7582.599.2421.261.9261.024.0841.024.084
Langfristet gæld til banker000000
Anden langfristet gæld000000
Leverandører af varer og tjenesteydelser20.501.97419.830.62825.481.550010.938.5330
Kortfristede forpligtelser338.908.822203.802.037526.876.317133.002.349118.924.4320
Gældsforpligtelser359.521.816208.566.093545.784.828133.002.349118.924.432117.896.139
Forpligtelser359.521.816208.566.093545.784.828133.002.349118.924.432117.896.139
Passiver446.733.824283.420.395584.971.435149.607.751130.040.182124.798.838
Passiver
16.06.2023
Nøgletal
16.06.2023
Årsrapport
2022
16.06.2023
2021
17.05.2022
2020
15.06.2021
2019
03.06.2020
2018
24.05.2019
2016
03.05.2018
Afkastningsgrad 9,5 %10,7 %4,8 %5,9 %4,7 %5,5 %
Dækningsgrad 65,3 %83,4 %83,6 %37,1 %34,9 %35,2 %
Resultatgrad 6,6 %5,7 %6,4 %1,4 %1,2 %1,7 %
Varelagerets omsætningshastighed Na.Na.Na.Na.Na.Na.
Egenkapitals-forretning 68,3 %57,9 %58,2 %34,2 %41,7 %91,5 %
Payout-ratio 99,9 %100,0 %98,7 %Na.Na.Na.
Gældsdæknings-nøgletal 4.473,6 %1.467,0 %2.760,3 %968,7 %1.838,9 %1.882,9 %
Soliditestgrad 11,0 %13,1 %6,3 %10,3 %7,8 %4,7 %
Likviditetsgrad 123,0 %131,4 %107,0 %111,5 %108,1 %Na.
Resultat
16.06.2023
Gæld
16.06.2023
Årsrapport
16.06.2023
Nyeste:01.01.2022- 31.12.2022(offentliggjort: 16.06.2023)
Information om virksomhedens regnskabsklasse:The annual report for Novo Nordisk Denmark A/S has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class C enterprises (large enterprises).
Beretning
16.06.2023
Dato for ledelsens godkendelse af årsrapporten:2023-05-25
Beskrivelse af usædvanlige forhold, der kan have påvirket indregningen eller målingen:Unusual matters having affected the financial sattements The financial position at 31 December 2022 of the Company and the results of the activities of the Company for the financial year for 2022 have not been affected by any unusual matters.
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Managing Director have approved the annual report of Novo Nordisk Denmark A/S for the financial year 1 January - 31 December 2022.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Business review Novo Nordisk Denmark A/S (secondary name Novo Nordisk Region Europe Pharmaceuticals A/S and Novo Nordisk North West Europe Pharmaceuticals A/S) is selling medicine in the treatment areas diabetes, obesity, rare endocrine and blood disorders as well as hormone replacement treatment. The company is located in Ørestad in Copenhagen, Denmark. Number of average employees has increased from 176 in 2021 to 200 in 2022. Novo Nordisk Denmark A/S consist of the following three units: The Danish sales affiliate The unit is a fully operational sales affiliate with focus on the distribution of the medicine produced by Novo Nordisk A/S to patients in Denmark and Iceland. Novo Nordisk A/S and Novo Nordisk Healthcare AG bears all the risks for launches as well as research and development, hence launch costs and R&D costs are invoiced to Novo Nordisk A/S and Novo Nordisk Healthcare AG as service fee including a mark-up for internal costs. North West Europe regional office Service company supporting the business areas/large affiliates in Europe (UK, France, Spain, Switzerland, Netherlands, Denmark, Sweden and business area North West Europe mid-size). All costs, both internal and external are invoiced to Novo Nordisk A/S as service fee including a mark-up for internal costs. North West Europe mid size business area office Service company supporting the affiliates in business area North West Europe mid-size (Norway, Finland, Belgium, Austria, Portugal and Ireland). All costs, both internal and external are invoiced to the affiliates in business area NWE mid-size and to Novo Nordisk A/S.
Vi bruger cookies til at øge oplevelsen og målrette vores markedsføring.
Ved at klikke OK tillader du brug af cookies. Læs mere her.
OK